Gilead Sciences, Inc. has named Andrew Cheng, MD, PhD to executive vice president, HIV therapeutics and development operations, and Taiyin Yang, PhD, to the role of executive vice president, pharmaceutical development and manufacturing. Dr. Cheng and Dr. Yang will both join Gilead’s senior leadership committee.
Dr. Cheng joined Gilead in 1999. He has led clinical development activities for the company’s development-stage programs in HIV/AIDS. In 2009, he was appointed senior vice president, HIV therapeutics and development operations, assuming additional responsibility for biometrics, clinical operations, clinical pharmacology, drug safety and public health, project management and regulatory affairs. Dr. Cheng reports to Norbert Bischofberger, PhD, executive vice president, research and development and chief scientific cfficer. Prior to joining Gilead, Dr. Cheng trained in internal medicine at the University of California, Los Angeles. He received his medical degree and PhD in cellular and molecular biology from Columbia University and his undergraduate degree from the Johns Hopkins University.
Dr. Yang joined Gilead in 1993 and was promoted to senior vice president in 2005. In her newly expanded role, Dr. Yang is responsible for managing pharmaceutical development, analytical operations, laboratory information, quality assurance and manufacturing of both clinical and commercial drug substances and drug products. She reports to Dr. Bischofberger and to John Milligan, PhD, president and chief operating officer. Prior to joining Gilead, Dr. Yang was director of analytical chemistry at Syntex. Dr. Yang received her bachelor’s degree in chemistry from National Taiwan University and her PhD in organic chemistry from the University of Southern California.
Source: Gilead Sciences